Mostrar el registro sencillo del ítem

Recommendations for the management of diabetic macular oedema with intravitreal dexamethasone implant: A national Delphi consensus study

dc.rights.licenseopenen_US
dc.contributor.authorKODJIKIAN, Laurent
dc.contributor.authorBAILLIF, Stephanie
dc.contributor.authorCOUTURIER, Aude
dc.contributor.authorCREUZOT-GARCHER, Catherine
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorDELYFER, Marie-Noelle
dc.contributor.authorMATONTI, Frederic
dc.contributor.authorWEBER, Michel
dc.date.accessioned2022-01-14T11:37:32Z
dc.date.available2022-01-14T11:37:32Z
dc.date.issued2021-11-13
dc.identifier.issn1724-6016 (Electronic) 1120-6721 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/124390
dc.description.abstractEnPURPOSE: The intravitreal dexamethasone implant (DEX-I) is an alternative to anti-VEGF for the first-line treatment of diabetic macular oedema (DME). However, several questions remain regarding its routine use and its place in certain situations not always specified in current recommendations. A national consensus approach was, therefore, initiated by French retinal experts. METHODS: An iterative Delphi consensus approach was used. A steering committee (SC) of seven experts analysed data from the literature to formulate statements divided into five key areas of treatment. These statements were submitted to the independent and anonymous electronic vote of 87 French retina experts among whom 39 expressed their opinion and therefore constituted the voting panel. RESULTS: After two rounds of voting, 22 and 7 of 38 statements received a strong consensus and a good consensus, respectively. The consensus level was higher for statements regarding first-line indications and safety of DEX-I compared to those regarding efficacy assessment, reprocessing time or pathophysiological biomarkers. The panellists recommended the preferential use of DEX-I for patients with limited availability for multiple injections, those who needed to undergo cataract surgery or who had a recent cardiovascular history, and as a therapeutic alternative to anti-VEGF in patients with a history of vitrectomy, retinal serous detachment, hyper-reflective points or dry exudates in optical coherence tomography (OCT). However, some statements proposed by SC experts were not validated. CONCLUSION: This study provides some key recommendations to clinicians treating diabetic macular oedema, which may be useful when using intravitreal dexamethasone implants in daily practice.
dc.language.isoENen_US
dc.subject.enDiabetic macular oedema
dc.subject.enDexamethasone
dc.subject.enIntravitreal implant
dc.subject.enDelphi consensus
dc.subject.enTreatment
dc.subject.enAntivascular endothelial growth factor
dc.title.enRecommendations for the management of diabetic macular oedema with intravitreal dexamethasone implant: A national Delphi consensus study
dc.typeArticle de revueen_US
dc.identifier.doi10.1177/11206721211052852en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed34779302en_US
bordeaux.journalEuropean Journal of Ophthalmologyen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamLEHA_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=European%20Journal%20of%20Ophthalmology&rft.date=2021-11-13&rft.eissn=1724-6016%20(Electronic)%201120-6721%20(Linking)&rft.issn=1724-6016%20(Electronic)%201120-6721%20(Linking)&rft.au=KODJIKIAN,%20Laurent&BAILLIF,%20Stephanie&COUTURIER,%20Aude&CREUZOT-GARCHER,%20Catherine&DELYFER,%20Marie-Noelle&rft.genre=article


Archivos en el ítem

ArchivosTamañoFormatoVer

No hay archivos asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem